$ 0.2649

+0.0121(4.7864%)

05-19 11:14

Tyme Technologies, Inc.

Tyme Technologies, Inc. operates as a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its clinical program, SM-88 is a novel combination therapy based on dysfunctional metyrosine derivatives and has shown complete or partial imaging responses in 15 different cancer subtypes, including solid tumors, sarcomas, gliomas and hematological malignancies, without demonstrating drug-related severe adverse events. The company was founded on November 22, 2011 and is headquartered in New York, NY.
最高:0.2700今开:0.2500成交量:42.15万股换手:0.24%
最低:0.2500昨收:0.2528成交额:11.12万振幅:7.91%
52周最高:2.0200量比:0.58市盈率(TTM):亏损市净率:0.53
52周最低:0.2187委比:42.86%市盈率(静):亏损市销率:--
每股收益:-0.14股息(TTM):--每手股数:1总市值:4561.76万
每股净资产:0.50股息率(TTM):--最小价差:0.0001总股本:1.72亿
机构持股:--Beta:--空头回补天数:--货币单位:USD
最新获投
暂无数据
最新动态
暂无数据
五力模型
暂无数据
财务指标
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
流动资产
2,346.87万
3,101.46万
1,260.06万
869.64万
1,178.39万
现金及短期投资
2,243.86万
2,897.58万
1,080.58万
751.34万
1,050.18万
短期应收账款
--
--
--
--
--
存货
--
--
--
--
--
其他流动资产
103.01万
203.88万
179.49万
118.29万
128.21万
非流动资产
160.59万
3,239.00
4,313.00
5,387.00
6,461.00
厂房及设备净资产
1.64万
3,239.00
4,313.00
5,387.00
6,461.00
项目总投资及垫款
--
--
--
--
--
长期应收票据
--
--
--
--
--
无形资产
--
--
--
--
--
递延所得税资产
--
--
--
--
--
其他资产
158.94万
--
--
--
--
合计总资产
2,507.46万
3,101.78万
1,260.50万
870.17万
1,179.04万
流动负债
298.70万
454.59万
371.38万
305.19万
321.44万
短期债务(含部分LTD)
26.93万
48.01万
--
--
--
应付账款
124.43万
--
--
--
--
应付所得税
--
--
--
--
--
其他流动负债
147.33万
406.58万
371.38万
305.19万
321.44万
非流动负债
0.00
0.00
0.00
0.00
0.00
长期负债
--
--
--
--
--
拨备风险及费用
--
--
--
--
--
递延所得税负债
--
--
--
--
--
其他负债
--
--
--
--
--
合计总负债
298.70万
454.59万
371.38万
305.19万
321.44万
股东权益合计
2,208.76万
2,647.20万
889.11万
564.99万
857.59万
非股权储备
--
--
--
--
--
优先股-账面价值
0.00
0.00
0.00
0.00
0.00
普通股权益(合计)
2,208.76万
2,647.20万
889.11万
564.99万
857.59万
累计少数股东权益
--
--
--
--
--
权益总额
2,208.76万
2,647.20万
889.11万
564.99万
857.59万
负债与股东权益合计
2,507.46万
3,101.78万
1,260.50万
870.17万
1,179.04万
每股账面价值
0.22
0.26
0.10
0.06
0.10
每股账面价值-有形
0.22
0.26
0.10
0.06
0.10
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
营业总收入
--
--
--
--
--
-营业成本
2,369.00
1,074.00
1,074.00
1,074.00
1,074.00
毛利
-2,369.00
-1,074.00
-1,074.00
-1,074.00
-1,074.00
-销售管理及行政费用
671.68万
531.21万
556.02万
529.58万
318.75万
-其他运营费用
--
--
--
--
--
计息税前利润
-671.92万
-531.31万
-556.13万
-529.69万
-318.86万
+非经营收入(支出)
--
--
--
--
31.56万
-非经常性支出
--
--
--
-7.48万
--
-利息支出
3,627.00
--
--
--
--
税前净利润
-672.28万
-531.31万
-556.13万
-522.22万
-287.29万
-所得税
--
--
--
--
--
+其他税后调整
0.00
0.00
0.00
0.00
0.00
+联署公司盈利权益
--
--
--
--
--
合并净利润
-672.28万
-531.31万
-556.13万
-522.22万
-287.29万
-少数股东权益开支
--
--
--
--
--
净利润
-672.28万
-531.31万
-556.13万
-522.22万
-287.29万
-优先股股息
--
--
--
--
--
一般可用收入净利润
-672.28万
-531.31万
-556.13万
-522.22万
-287.29万
每股基本收益
-0.07
-0.06
-0.06
-0.06
-0.03
摊薄每股收益
-0.07
-0.06
-0.06
-0.06
-0.03
息税折旧摊销前利润
-671.68万
-531.21万
-556.02万
-529.59万
-318.75万
单位:美元
2018-03-31
2017-03-31
2015-12-31
2014-11-30
净收益
-1,896.95万
-1,520.68万
-1,172.68万
-5.39万
+折旧损耗及摊稍
4,296.00
4,281.00
4,292.00
--
+递延税及投资税减免
--
--
--
--
+其他经营基金
729.89万
807.21万
472.46万
--
营运资金
-1,166.62万
-713.04万
-699.80万
-5.39万
+特别项目
--
--
--
--
+营运资金变动
-21.30万
126.93万
38.78万
-3,757.00
经营现金流
-1,187.93万
-586.11万
-661.02万
-5.77万
资本支出
--
--
--
--
收购所得净资产
--
--
--
--
固定资产和业务出售收入
--
--
--
--
投资买卖净额
--
--
--
--
非现金项目
0.00
0.00
0.00
0.00
投资现金流
--
--
--
--
发放现金股利
--
--
--
--
股本变动
3,019.71万
1,047.09万
723.10万
--
发行/削减债务净额
--
-23.21万
131.58万
--
其他融资基金
17.50万
--
250.00万
5.77万
筹资现金流
3,037.21万
1,023.88万
1,104.67万
5.77万
汇率影响
--
--
--
--
杂项基金
--
--
--
--
现金净流动
1,849.28万
437.77万
443.66万
--
自由现金流
-1,187.93万
-586.11万
-661.02万
-5.77万
公司高管
Timothy C. Tyson
Timothy C. Tyson is a businessperson who founded Thayer Leader Development Group, Inc. and who has been the head of 8 different companies. Currently, he is Chairman at Icagen-T, Inc., Chairman & Chief Executive Officer at Avara Pharmaceutical Services, Inc., Chairman & Chief Executive Officer at Avara Norman Pharmaceutical Services, Inc. (a subsidiary of Avara Pharmaceutical Services, Inc.), Chairman at Icagen, Inc. and President of Alkaloida Chemical Co. Ltd. Mr. Tyson is also on the board of Tyme Technologies, Inc., Tyme, Inc. and ICN Hungary Co. Ltd. and Chief Executive Officer-Roundtable at the University of California, Irvine. In the past he was Executive Chairman of Laurus Labs Ltd., Vice President & General Manager at GlaxoSmithKline Plc and President-Global Manufacturing & Supply at Glaxo Wellcome Plc (a subsidiary of GlaxoSmithKline Plc), Operations Manager at Procter & Gamble Co., Chairman for Aptuit LLC, President & Chief Executive Officer for Valeant Pharmaceuticals International Corp. and Director-Leadership Forum at International Society for Pharmaceutical Engineering. Mr. Tyson received an MBA and a graduate degree from Jacksonville State University and an undergraduate degree from US Military Academy.
Tommy George Thompson
Mr. Tommy G. Thompson is a Chairman at Vital Decisions LLC, a Chairman-Trustees Board at Physicians Realty Trust, a Chairman at TherapeuticsMD, Inc., an Independent Director at United Therapeutics Corp., an Independent Director at Centene Corp., a Chairman & Chief Executive Officer at Thompson Holdings, Inc., a Member at State Bar of Wisconsin, a Member at The District of Columbia Bar and an Operating Partner at Windrose Health Investors LLC. He is on the Board of Directors at Tyme Technologies, Inc., United Therapeutics Corp., Centene Corp., Accordia Global Health Foundation, Armada Media Corp., Cleveland HeartLab, Inc. and Medical Missions For Children, Inc. Mr. Thompson was previously employed as a Chairman by Stayhealthy, Inc., an Independent Director by Cytori Therapeutics, Inc., an Independent Director by Cancer Genetics, Inc., a Chairman by AGA Medical Holdings, Inc., an Independent Director by C.R. Bard, Inc. (New Jersey), a Chairman by AGA Medical Corp., a Chairman by CareView Communications, Inc., a Senior Partner by Akin, Gump, Strauss, Hauer & Feld LLP, an Independent Chairman by The Deloitte Center for Health Solutions, a Chairman by Logistics Health, Inc., a Chairman by The Global Fund to Fight AIDS, Tuberculosis & Malaria, a Secretary & Governor by US Department of Health & Human Services (DC), a Governor by State of Wisconsin, a Venture Partner by Burrill & Co. LLC, a Chairman by Education Commission of the States, a Chairman by Midwestern Governors Conference, and a Chairman by National Governors Association. He also served on the board at Tyme, Inc., Tenex Health, Inc., CNS Response, Inc., SpectraScience, Inc., Medco Health Solutions, Inc., PURE Bioscience, Inc., VeriChip Corp., Harmony Information Systems, Inc., Picis, Inc., ProCure Treatment Centers, Inc., Voyager Pharmaceutical Corp. and X-Shares Advisors LLC. He received his undergraduate degree from the University of Wisconsin and a graduate degree from the University of Wisconsin.
James Biehl
James Biehl is on the board of Tyme Technologies, Inc. and Member of American Bar Association, Member of New Jersey State Bar Association, Member of Philadelphia Bar Association, Member of Pennsylvania State Bar Association and Partner at Drinker Biddle & Reath LLP. Mr. Biehl received a graduate degree from Temple University (Pennsylvania) and an undergraduate degree from Carnegie Mellon University.
Jonathan M. Eckard
Jonathan M. Eckard occupies the position of Chief Scientific Affairs Officer at Tyme Technologies, Inc. In the past Dr. Eckard held the position of Biotechnology Equity Research Analyst at Leerink Swann & Co., Biotechnology Analyst at Barclays Capital, Inc., Associate at HSBC Securities USA, Inc., Biotechnology Analyst at Citigroup Global Markets, Inc. (Broker) and Graduate Research Assistant at New York University School of Medicine. Dr. Eckard received an undergraduate degree from The Ohio University and a doctorate and a graduate degree from New York University School of Medicine.
David P. Carberry
David P. Carberry is on the board of Tyme Technologies, Inc. In his past career he was Vice President-Finance of Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance of Johnson & Johnson-Merck Consumer Pharmaceuticals Co., Chief Financial Officer & Vice President-Finance at Johnson & Johnson Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance at Independence Technology LLC and Chief Financial Officer at Aldagen, Inc. David P. Carberry received an MBA from Drexel University and an undergraduate degree from LaSalle University.
Timothy C. Tyson
Timothy C. Tyson is a businessperson who founded Thayer Leader Development Group, Inc. and who has been the head of 8 different companies. Currently, he is Chairman at Icagen-T, Inc., Chairman & Chief Executive Officer at Avara Pharmaceutical Services, Inc., Chairman & Chief Executive Officer at Avara Norman Pharmaceutical Services, Inc. (a subsidiary of Avara Pharmaceutical Services, Inc.), Chairman at Icagen, Inc. and President of Alkaloida Chemical Co. Ltd. Mr. Tyson is also on the board of Tyme Technologies, Inc., Tyme, Inc. and ICN Hungary Co. Ltd. and Chief Executive Officer-Roundtable at the University of California, Irvine. In the past he was Executive Chairman of Laurus Labs Ltd., Vice President & General Manager at GlaxoSmithKline Plc and President-Global Manufacturing & Supply at Glaxo Wellcome Plc (a subsidiary of GlaxoSmithKline Plc), Operations Manager at Procter & Gamble Co., Chairman for Aptuit LLC, President & Chief Executive Officer for Valeant Pharmaceuticals International Corp. and Director-Leadership Forum at International Society for Pharmaceutical Engineering. Mr. Tyson received an MBA and a graduate degree from Jacksonville State University and an undergraduate degree from US Military Academy.
Tommy George Thompson
Mr. Tommy G. Thompson is a Chairman at Vital Decisions LLC, a Chairman-Trustees Board at Physicians Realty Trust, a Chairman at TherapeuticsMD, Inc., an Independent Director at United Therapeutics Corp., an Independent Director at Centene Corp., a Chairman & Chief Executive Officer at Thompson Holdings, Inc., a Member at State Bar of Wisconsin, a Member at The District of Columbia Bar and an Operating Partner at Windrose Health Investors LLC. He is on the Board of Directors at Tyme Technologies, Inc., United Therapeutics Corp., Centene Corp., Accordia Global Health Foundation, Armada Media Corp., Cleveland HeartLab, Inc. and Medical Missions For Children, Inc. Mr. Thompson was previously employed as a Chairman by Stayhealthy, Inc., an Independent Director by Cytori Therapeutics, Inc., an Independent Director by Cancer Genetics, Inc., a Chairman by AGA Medical Holdings, Inc., an Independent Director by C.R. Bard, Inc. (New Jersey), a Chairman by AGA Medical Corp., a Chairman by CareView Communications, Inc., a Senior Partner by Akin, Gump, Strauss, Hauer & Feld LLP, an Independent Chairman by The Deloitte Center for Health Solutions, a Chairman by Logistics Health, Inc., a Chairman by The Global Fund to Fight AIDS, Tuberculosis & Malaria, a Secretary & Governor by US Department of Health & Human Services (DC), a Governor by State of Wisconsin, a Venture Partner by Burrill & Co. LLC, a Chairman by Education Commission of the States, a Chairman by Midwestern Governors Conference, and a Chairman by National Governors Association. He also served on the board at Tyme, Inc., Tenex Health, Inc., CNS Response, Inc., SpectraScience, Inc., Medco Health Solutions, Inc., PURE Bioscience, Inc., VeriChip Corp., Harmony Information Systems, Inc., Picis, Inc., ProCure Treatment Centers, Inc., Voyager Pharmaceutical Corp. and X-Shares Advisors LLC. He received his undergraduate degree from the University of Wisconsin and a graduate degree from the University of Wisconsin.
James Biehl
James Biehl is on the board of Tyme Technologies, Inc. and Member of American Bar Association, Member of New Jersey State Bar Association, Member of Philadelphia Bar Association, Member of Pennsylvania State Bar Association and Partner at Drinker Biddle & Reath LLP. Mr. Biehl received a graduate degree from Temple University (Pennsylvania) and an undergraduate degree from Carnegie Mellon University.
Jonathan M. Eckard
Jonathan M. Eckard occupies the position of Chief Scientific Affairs Officer at Tyme Technologies, Inc. In the past Dr. Eckard held the position of Biotechnology Equity Research Analyst at Leerink Swann & Co., Biotechnology Analyst at Barclays Capital, Inc., Associate at HSBC Securities USA, Inc., Biotechnology Analyst at Citigroup Global Markets, Inc. (Broker) and Graduate Research Assistant at New York University School of Medicine. Dr. Eckard received an undergraduate degree from The Ohio University and a doctorate and a graduate degree from New York University School of Medicine.
David P. Carberry
David P. Carberry is on the board of Tyme Technologies, Inc. In his past career he was Vice President-Finance of Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance of Johnson & Johnson-Merck Consumer Pharmaceuticals Co., Chief Financial Officer & Vice President-Finance at Johnson & Johnson Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance at Independence Technology LLC and Chief Financial Officer at Aldagen, Inc. David P. Carberry received an MBA from Drexel University and an undergraduate degree from LaSalle University.
高管交易状态
暂无数据
持股状况
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Invesco Advisers, Inc.
79252
0.08%
79252
--
2018-06-30
Northern Trust Investments N A
373596
0.37%
373596
--
2018-06-30
State Street Corp
585991
0.58%
585991
--
2018-06-30
Millennium Management LLC
900000
0.89%
-651315
-41.98%
2018-06-30
Farallon Capital Management, L.L.C.
948390
0.94%
-481899
-33.69%
2018-06-30
Ardsley Advisory Partners
1033500
1.02%
98500
10.53%
2018-06-30
Vanguard Group Inc
1165289
1.15%
134903
13.09%
2018-06-30
BlackRock Inc
1649435
1.63%
1649435
--
2018-06-30
Healthcare Value Capital LLC
2075000
2.05%
--
--
2018-06-30
BlackRock Institutional Trust Company NA
345118
0.34%
345118
--
2018-06-30
HighTower Advisors, LLC
340000
0.34%
--
--
2018-03-31
Weiss Multi-Strategy Advisers Llc
155000
0.15%
-35000
-18.42%
2018-06-30
TIAA-CREF Investment Management LLC
84231
0.08%
84231
--
2018-06-30
Morgan Stanley & Co Inc
89619
0.09%
76784
598.24%
2018-06-30
Northern Trust Asset Management
101260
0.10%
-540
-0.53%
2018-07-31
1492 Capital Management, LLC
96881
0.10%
26681
38.01%
2018-06-30
Perkins Capital Management Inc
101050
0.10%
77550
330.00%
2018-06-30
Moore Capital Management, LP
150000
0.15%
150000
--
2018-03-31
Geode Capital Management, LLC
108508
0.11%
108508
--
2018-06-30
Family Management Corporation
140000
0.14%
--
--
2018-06-30
Morgan Stanley Smith Barney LLC
76107
0.08%
40061
111.14%
2018-06-30
Charles Schwab Investment Management Inc
78400
0.08%
78400
--
2018-06-30
Teachers Advisors Inc
55310
0.05%
55310
--
2018-06-30
California State Teachers Retirement Sys
64288
0.06%
64288
--
2018-06-30
BNY Mellon Investment Management
71539
0.07%
71539
--
2018-06-30
FMG LLC
87851
0.09%
87851
--
2018-06-30
Susquehanna Financial Group, LLLP
97846
0.10%
97846
--
2018-03-31
BlackRock
95228
0.09%
95228
--
2018-06-30
Goldman, Sachs & Co.
280868
0.28%
264145
1579.53%
2018-03-31
BlackRock Fund Advisors
1428759
1.12%
-142
-0.01%
2018-08-23
OPERS
53984
0.05%
53984
--
2018-06-30
Jennison Associates LLC
300000
0.30%
300000
--
2018-03-31
UBS O'Connor LLC
71233
0.07%
71233
--
2018-03-31
Tudor Investment Corp Et AL
50000
0.05%
50000
--
2018-03-31
Northern Trust Investments Inc
24714
0.02%
24714
--
2018-06-30
Jefferies & Company Inc
40800
0.04%
40800
--
2018-03-31
Deutsche Asset & Wealth Management Investment GmbH
13681
0.01%
--
--
2018-07-05
Verition Fund Managegment, LLC
17902
0.02%
17902
--
2018-03-31
Wells Fargo & Co
17302
0.02%
-831
-4.58%
2018-03-31
GLG Partners LP
23820
0.03%
23820
--
2017-12-31
Franklin Street Advisors Inc.
31000
0.03%
31000
--
2017-12-31
UBS Securities LLC
12468
0.01%
-1146
-8.42%
2018-03-31
Asset Planning Services Ltd
5000
0.01%
--
--
2017-12-31
Concept Capital Markets, LLC
5000
0.01%
--
--
2017-12-31
Susquehanna International Group, LLP
97846
0.10%
97846
--
2018-03-31
Wells Fargo Advisors, LLC
2850
--
--
--
2018-03-31
Royal Bank Of Canada
1000
--
--
--
2017-12-31
Wells Fargo Bank NA
8617
0.01%
420
5.12%
2018-03-31
Credit Suisse First Boston (CSFB)
23820
0.03%
23820
--
2017-12-31
BlueCrest Capital Management Ltd.
38708
0.04%
38708
--
2017-12-31
Wells Fargo Funds Management LLC
7352
0.01%
-1175
-13.78%
2018-01-31
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Russell 2000 Growth ETF
30145
0.03%
--
--
2018-07-31
Schwab Small Cap Index
78400
0.08%
--
--
2018-07-31
CREF Stock R1
84231
0.08%
--
--
2018-07-31
Invesco All Cap Market Neutral A
79252
0.08%
79252
--
2018-06-30
iShares Micro-Cap
111070
0.11%
--
--
2018-09-12
Northern Trust Russell 2000 Index Fund - DC - Non-Lending
101260
0.10%
-540
-0.53%
2018-07-31
Wells Fargo Traditional Sm Cap Gr A
97709
0.10%
97709
--
2018-07-31
iShares Russell 2000 Growth
414668
0.42%
-400
-0.10%
2018-09-12
Vanguard Total Stock Mkt Idx
926156
0.91%
--
--
2018-07-31
The Vanguard Russell 2000 Growth Index
74328
0.07%
--
--
2018-07-31
BlackRock Russell 2500
60600
0.06%
60600
--
2018-06-30
AXA 2000 Managed Volatility K
62733
0.06%
4638
7.98%
2018-07-31
Master Small Cap Index
30530
0.03%
2257
7.98%
2018-07-31
BNY Mellon EB DL Small Cap SIF
29137
0.03%
29137
--
2018-06-30
Vanguard Balanced Index Inv
32398
0.03%
--
--
2018-07-31
Vanguard Russell 2000 ETF
47397
0.05%
882
1.90%
2018-07-31
TIAA-CREF Small-Cap Blend Idx Inst
51255
0.05%
--
--
2018-07-31
LVIP SSgA Small Cap Index Std
48800
0.05%
48800
--
2018-06-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls
55747
0.06%
--
--
2018-07-31
BlackRock Russell 2000
53984
0.05%
53984
--
2018-06-30
Northern Small Cap Index
24714
0.02%
24714
--
2018-06-30
Pacific Select Small-Cap Index I
15262
0.02%
15262
--
2018-06-30
Voya Russell Small Cap Index Port I
19380
0.02%
19380
--
2018-06-30
iShares Russell 3000
24555
0.02%
--
--
2018-08-03
Nationwide Small Cap Index A
7355
0.01%
7355
--
2018-06-30
Principal SmallCap Growth I Instl
6265
0.01%
6265
--
2018-06-30
State Street Small/Mid Cap Equity Index
5200
0.01%
5200
--
2018-06-30
ProShares Ultra Russell2000
3721
--
3721
--
2018-06-30
Weiss Alternative Balanced Risk I
3515
--
3515
--
2018-03-31
PowerShares Russell 2000 Equal Wt ETF
2189
--
--
--
2018-07-12
ProShares UltraPro Russell2000
2005
--
2005
--
2018-06-30
Wells Fargo Dow Jones Target 2030 A
1223
--
-204
-14.30%
2018-05-31
Wells Fargo Dow Jones Target 2040 A
1316
--
-195
-12.91%
2018-05-31
GE Investments Total Return 1
1007
--
1007
--
2018-06-30
Wells Fargo Dow Jones Target 2050 R6
763
--
-118
-13.39%
2018-05-31
Wells Fargo Dow Jones Target 2020 A
718
--
-132
-15.53%
2018-05-31
Wells Fargo Dow Jones Target 2035 R6
640
--
-58
-8.31%
2018-05-31
Wells Fargo Dow Jones Target 2015 R6
115
--
-14
-10.85%
2018-05-31
Wells Fargo Dow Jones Target 2055 R6
170
--
-10
-5.56%
2018-04-30
Wells Fargo Dow Jones Target 2045 R6
509
--
-34
-6.26%
2018-04-30
Wells Fargo Dow Jones Target 2025 R6
554
--
-34
-5.78%
2018-04-30
Wells Fargo Dow Jones Target 2010 A
95
--
-9
-8.65%
2018-04-30
Wells Fargo Dow Jones Target 2060 A
50
--
1
2.04%
2018-04-30
Wells Fargo Dow Jones Target Today A
80
--
-6
-6.98%
2018-04-30